Biologic Drugs

Oct 26, 2017
By Pharmaceutical Technology Editors
The new BioLive event, which will be a global hub for biopharmaceutical manufacturing, will launch alongside CPhI Worldwide 2018 in Madrid.
Oct 25, 2017
By Pharmaceutical Technology Editors
ABEC, an equipment and engineering company, will provide a custom-made, single-use bioreactor to custom manufacturing firm, Emergent, for its Maryland manufacturing facility.
Oct 24, 2017
By Pharmaceutical Technology Editors
The biopharmaceutical company has received a $4.2-million grant from the Bill & Melinda Gates Foundation to invest in the development of new treatments for Enterotoxigenic Escherichia coli infections, a bacterial cause of diarrhea in the developing world.
Oct 23, 2017
By Pharmaceutical Technology Editors
The $72-million investment, part of a larger $850-million investment into its US operations, will allow the drugmaker to replace an outdated insulin vial-filling line and to upgrade technology at its Indianapolis manufacturing plant.
Oct 20, 2017
By Pharmaceutical Technology Editors
The companies aim to use CureVac’s proprietary messenger RNA technology to develop and commercialize up to five potential cancer vaccine products.
Oct 20, 2017
By Pharmaceutical Technology Editors
This approval marks the second gene therapy to be approved by FDA and the first to be approved for certain types of non-Hodgkin lymphoma.
Oct 16, 2017
By Pharmaceutical Technology Editors
The company announced plans to expand its viral vector process development facilities in the United States and its cleanroom facilities in the Netherlands for vector-based products.
Oct 16, 2017
By Pharmaceutical Technology Editors
The vaccine is a non-live, recombinant subunit vaccine that combines an antigen and an adjuvant system to trigger a targeted and long-lasting immune response to the shingle-causing virus.
Oct 16, 2017
By Pharmaceutical Technology Editors
Stelara (ustekinumab), already approved for treating adults, is now also approved for treating adolescents with moderate to severe plaque psoriasis.
Oct 14, 2017
By Pharmaceutical Technology Editors
Samsung BioLogics’ second facility adds 152,000 L of mAb drug substance capacity.
native1_300x100
lorem ipsum